About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Evaluation of Relapse Presence in Multiple Sclerosis

NCT05218317·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Marmara University

Age

18–85

Sex

ALL

Healthy volunteers

Accepted

You may be eligible if

Patients for whom the administration of intravenous corticosteroids was decided due to the diagnosis of new relapse
Patients who were followed up with the diagnosis of RRMS
Healthy controls

You may not be if

Being younger than 18 years old
Having any other neurological or metabolic diseases
Ophthalmological diseases
A history of optic neuritis and trigeminal symptoms
Ocular trauma or surgery
Contact lens use
The patients who had a relapse attack 6 months prior to the study

The record

StatusCompleted

PhaseNo phase

Taking part87

StartedJan 2021

UpdatedFeb 1, 2022

Conditions

Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis Relapse

Where1

Marmara University
Istanbul, Turkey (Türkiye)

Clareo Health | Evaluation of Relapse Presence in Multiple Sclerosis